Hyperbaric oxygen treatment results in a group of... (2020 study) Skip to main content
Clinical Study Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc 2020

Hyperbaric oxygen treatment results in a group of Turkish central retinal artery occlusion patients with a combined presence of thrombophilic mutations.

Çevik MÖ, Bagli BS, Çevik SG, Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc, 2020

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers looked at 11 people with non-arteritic central retinal artery occlusion (a blocked artery in the eye) who had hyperbaric oxygen therapy, and checked their vision before and after and their genes for clotting-related mutations.

What They Found

In this small group of 11 patients, six (54%) responded to hyperbaric oxygen therapy and five (46%) did not. Patients admitted before 12 hours responded well. Eight patients (72%) had the MTHFR 677T allele, five (45%) had the MTHFR 1298C allele, and 10 (91%) had the PAI-1-675 4G allele. No Factor V Leiden mutations and only one Factor II G20210A mutation were seen. The authors reported that no systemic diseases and no advanced age were statistically correlated with the blockage, and they suggested that a combination of mutations, rather than a single one, could be responsible.

What This Means for Canadian Patients

For people with central retinal artery occlusion, this study reports that about half of the 11 patients responded to hyperbaric oxygen therapy, and almost as many did not. The authors state that timing seemed to matter, with those admitted before 12 hours responding well. The abstract does not give details of the treatment protocol, so it cannot guide specific treatment decisions.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The study included only 11 patients, had no comparison group reported in the abstract, and the link between the genetic mutations and the artery blockage is described only as probable, so no cause-and-effect conclusions can be drawn.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Clinical Study
Category Ocular / Retinal
Source Pubmed
PubMed ID 32176948
Year Published 2020
Journal Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc
MeSH Terms Adult; Aged; Factor V; Female; Humans; Hyperbaric Oxygenation; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Mutation; Plasminogen Activator Inhibitor 1; Prothrombin; Retinal Artery Occlusion; Time-to-Treatment; Treatment Outcome

Cite This Study

Share

Find a Canadian Clinic Treating Ocular / Retinal

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 1, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology